The Oncotype DX® Genomic Prostate Score Report

The evolved Genomic Prostate Score report provides even more clarity on the benefit of the Oncotype DX Genomic Prostate Score. The new report now includes data from 2 large independent cohorts and gives an even more precise risk estimate for each patient. Together, the updated report format and combined data increases the usefulness of the assay to further help you and patients make appropriate treatment decisions.


First Page of the Report

All Patient Information in One Place

 NCCN Report

Clear, Two Line Explanation


  • New graphic clearly shows starting NCCN® and group movement based on LFP
  • New language makes interpretation and patient discussions much simpler


GPS Relative to Other Patients

GPS Distribution
  • Can address the question, “How does my cancer compare to other prostate cancers with similar clinical features?”
  • Shows relative movement even when risk group doesn’t change
  • Gives meaning to GPS alone
  • Description makes interpretation of new information more straightforward


Updated Pathology Risk Information

Pathology Risk

  • Easier to see information about Low Grade and Organ Confined likelihoods
  • More clearly defines what is meant by low grade and organ confined disease
  • Helps physicians and patients understand definition of favorable pathology


Second Page of the Report

Updated References

GPS Results

  • GPS description gives high level overview of product
  • Clinical experience now includes meta-analysis patient totals1 (combination of 2 large independent cohorts)
  • References updated with second validation and meta-analysis publications1 (combination of 2 large independent cohorts)
  • Expected ranges clearly define LFP cut points between very low-low-intermediate


Download a Sample Report to See What Has Changed



1. Brand TC, et al. Urology 2016;89: 69-75

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.3.2016. ©National Comprehensive Cancer Network, Inc. 2016. All rights reserved. To view the most recent and complete version of the guideline, go online to


Next: Guidelines